TABRECTA

This brand name is authorized in Austria, Brazil, Canada, Spain, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Romania, United States

Active ingredients

The drug TABRECTA contains one active pharmaceutical ingredient (API):

1 Capmatinib UNII TY34L4F9OZ - CAPMATINIB

Capmatinib is an inhibitor of the MET receptor tyrosine kinase. Capmatinib inhibits MET phosphorylation (both autophosphorylation and phosphorylation triggered by the ligand hepatocyte growth factor [HGF]), MET-mediated phosphorylation of downstream signalling proteins, as well as proliferation and survival of MET-dependent cancer cells. Read about Capmatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TABRECTA Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
TABRECTA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX17		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 526521080099201, 526521080099301
Country: CA	Health Products and Food Branch	Identifier(s): 02527391, 02527405
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1221650002, 1221650004
Country: FR	Base de données publique des médicaments	Identifier(s): 64594989, 66287227
Country: HK	Department of Health Drug Office	Identifier(s): 66992, 66993
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9133, 9134
Country: IT	Agenzia del Farmaco	Identifier(s): 050167016, 050167028, 050167030, 050167042
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291067F1023, 4291067F2020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095017, 1095018, 1095019, 1095020
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69172001, W69173001
Country: US	FDA, National Drug Code	Identifier(s): 0078-0709, 0078-0716